SCHEMBL3403383

SCHEMBL3403383

CCN(CC)CCN(C)C(=O)c1sc(-c2ccc(Cl)c(C(F)(F)F)c2)nc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.44
HDAC4 P56524 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
DHODH Q02127 2/20 0.42
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
GAA P10253 2/20 0.41
KMT2A Q03164 2/20 0.40
NOTUM Q6P988 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
HTR2C P28335 2/20 0.40
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
RORB Q92753 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403876 0.88 KMT2A (0.45) PPARAHDAC4HDAC2HDAC8HDAC6
SCHEMBL3396808 0.85 KMT2A (0.45) PPARAHDAC4HDAC2HDAC8HDAC6
SCHEMBL3405487 0.83 HTR2C (0.44) PPARAHDAC4HDAC2HDAC8HDAC6
SCHEMBL3404554 0.83 HTR2C (0.44) PPARAHDAC4HDAC2HDAC8HDAC6
SCHEMBL3405267 0.82 ALDH1A1 (0.63) PPARAHDAC4HDAC2HDAC8HDAC6
SCHEMBL3398779 0.82 PPARA (0.48) PPARAHDAC4HDAC2HDAC8HDAC6
SCHEMBL3400771 0.81 HTR2C (0.45) PPARAHDAC4HDAC2HDAC8HDAC6
SCHEMBL3401487 0.81 HTR2C (0.55) PPARAHDAC4HDAC2HDAC8HDAC6
SCHEMBL3404304 0.81 KMT2A (0.61) ALDH1A1SMN1; SMN2NPC1GAAKMT2A
SCHEMBL3404493 0.80 KMT2A (0.44) PPARAALDH1A1SMN1; SMN2NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 PPARA 492/4885HDAC4 88/4885HDAC2 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.